RE: Results8 Sep 2021 09:13
Financial highlights
· Group revenues increased by 12% to £6.8m (H1 2020: £6.1m, at 21% constant currency)
· Orthopaedic and Dental division recorded a 26% increase in revenues (37% constant currency) to £4.3m (H1 2020: £3.4m), driven by strong underlying performance in the US market
· Gross profit of £3.1m (H1 2020: £2.9m), delivered at a 46% gross margin (2020: 46%)
· EBITDA loss reduced 48% to £1.1m (H1 2020: £2.1m) due to sales growth and tight expense management
· Cash position of £6.6m (H1 2020: £13.7m)
Commercial highlights
· US product shipments increased by 44% in H1 2021 compared with the same period in 2020
Operational highlights
· Restructuring of US commercial operations providing savings of US c.$350k in H1 2021
· Phase one expansion of the San Antonio facility completed on time and on budget
· Both government backed loans (part of the COVID-19 relief programme) have been forgiven
· Appointment of David ****e as Chief Financial Officer
· Trevor Phillips and Brian Phillips appointed to the Board as Independent Non-Executive Directors
Post balance sheet events
· Two additional products added to the Biosurgery portfolio, DermaPure Mesh and VNEW®